Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Integration of longitudinal ctdna MRD and PET/CT enhances prognostic stratification in newly diagnosed diffuse large B-cell lymphoma: A prospective multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

SZShunjin ZhangXLXiao LiuDZDehui Zou

Discussion

Loading...

Member takes

Overview

Prospective study shows improved progression-free survival in newly diagnosed DLBCL with integrated ctDNA and PET/CT monitoring, indicating better risk assessment.

Key Points

  • This study aimed to evaluate the prognostic utility of ctDNA and PET/CT for stratifying risk in DLBCL patients.
  • Conducted as a prospective multicenter study with newly diagnosed DLBCL patients.
  • Utilized serial plasma samples for ctDNA MRD tracking and PET/CT imaging.
  • Assessed clinical responses based on Lugano 2014 criteria.
  • At end of treatment, the complete response rate was 83.8%.
  • Two-year progression-free survival was 75.2%.
  • MRD positivity significantly correlated with worse outcomes, as indicated by lower progression-free survival rates.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236daeehttps://doi.org/10.1182/blood-2025-5323
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Liquid biopsy at the finish line: End-of-treatment ctDNA predicts relapse and survival in diffuse large B-cell lymphoma.2026
  2. 2Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma2024 · 10 citations
  3. 3Circulating tumor DNA-based minimal residual disease assessment predicts progression-free survival in diffuse large B-cell lymphoma: A systematic review and meta-analysis2025 · 1 citations
  4. 4Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study2026 · 1 citations
  5. 5Prognostic value of minimal residual disease detection by circulating tumor DNA in Hodgkin lymphoma.2025